Every year, European healthcare providers and insurers spend billions of Euros on ineffective chemotherapies that do not benefit the patients. With our proprietary Reverse Clinical Engineering® technology, we from ASC Oncology can support patients and physicians to ensure a better and more effective treatment for each individual patient.
ASC Oncology
We founded ASC Oncology to address one of the most pressing challenges in modern oncology: providing patients with the right therapy at the right time.
Chemotherapy fails for around half of the world’s cancer patients. Therapy-resistant tumors are responsible for the majority of cancer deaths and burden healthcare systems considerably.
With approximately 20 million new cancer cases worldwide every year, the successful treatment of cancer patients through individualised therapies has enormous potential. ASC Oncology seeks to identify the best possible chemotherapy for each patient and rule out those which will probably prove to be ineffective.
„We believe that the ASC Oncology approach will significantly enhance patient treatment, now and in the future. The revolutionary impact of our service will transform the field in a way similar to the digitalization of the music industry.“
Dr Christian Regenbrecht
Managing director, ASC Oncology GmbH
Management Team

Managing director
Biologist, PhD
Co-founder of ASC Oncology GmbH

Managing director
Lawyer
Co-founder of ASC Oncology GmbH

Business Development
Business Administrator, BSc
Other associates

Senior Advisor
Dr. med.
Shareholder of ASC Oncology GmbH

Laboratory Manager NMI-TT Berlin
PhD
Co-founder of ASC Oncology GmbH

Deputy director NMI Reutlingen
Biochemist, PhD
Co-founder of ASC Oncology GmbH

Pharma expert
Translational cancer research

Administration Manager NMI
Magistra Artium
Representative of the NMI at ASC GmbH

VP Business Development
Nuvisan Innovation Campus Berlin
PhD
Co-founder of ASC Oncology GmbH

Director of the Pathology Institute, Georg-August University Göttingen
Pathologist, Prof. Dr. med.
Co-founder of ASC Oncology GmbH

Inventor of the DigiWest technology
Biologist, PhD
Co-founder of ASC Oncology GmbH
Advisory Board

Prof. Dr. med.
Full Professor at the Faculty of Health, Medicine and Life Sciences (FHML)
Adjunct Professor at the School of Life Sciences, Manipal University, India
Professorial Fellow at the Maastricht Economic and Social Research Institute on Innovation and Technology
Director of the European Centre for Public Health Genomics (ECPHG)

Dr. med. Dr. rer. nat.
Co-founder of CeGaT GmbH
Own practice for human genetics in Tübingen

Prof. Dr.
Joint Head of School of Cancer & Pharmaceutical Sciences
Richard Dimbleby Professor of Cancer Research, King’s College London and Professor of Molecular Oncology at University College London (UCL) Cancer Institute.

Dr. med. Dr. rer.nat.
Chair of the ESMO Patient Advocates Working Group
Founder of the Melanoma Patient Network Europe
Cancer Mission board member at European Commission

Senior Company Manager Healthcare Industry at Berliner Sparkasse
Collaborations
FAQ
We go one step further. Sequencing tumors, for example, can reveal changes in the genetic material that may be used as a target for treatment of your tumor. However, it’s not clear if the targeted treatment will work in your case. Recent studies have shown that only a fraction of patients (0.8 – 3%) have been able to benefit from a therapy chosen for its sequencing results (Tannock & Hickman, 2019). In contrast, ASC Oncology’s Reverse Clinical Engineering® uses a person’s own tumor model to directly test the cancer drugs’ efficacy. This allows a prediction to be made about how you will respond to therapy. Find out more about the test procedure under Science.
Your treating physician removes a small piece of cancer tissue during your surgery or biopsy and sends this directly to ASC Oncology’s laboratory. Our team of scientists multiplies the living tumor cells in the lab and grows “avatars” of your tumor, called ‘tumor organoids’. These avatars of the tumor can be used to test drugs that may be candidates for treating your tumor, allowing the most effective anticancer drug to be determined before therapy begins. Our results are an important decision-making aid for personalized anticancer therapy. Compared to following standard guideline recommended therapy, this approach has higher chances of treatment success. View a complete list of steps of the procedure here.
No, ASC Oncology does not replace your oncologist, but provides you and your doctor with additional information. Every patient and every cancer is unique. The results of the Reverse Clinical Engineering® test procedure will tell you and your oncologist which drugs are likely to be effective on your individual tumor. These additional insights increase the chance of receiving effective drug therapy right from the start and avoiding ineffective therapies along with potential side effects.
It varies. Depending on the quality of the tumor sample and the cancer entity, growing PD3D® tumor models can take different amounts of time. On average, the Reverse Clinical Engineering® test procedure takes 28 days from receiving the sample to preparing the final report.
Please do not send a sample without letting us know in advance. Please contact us at 0800 6988667 or use our online form to register a patient and send a sample. We will organize the pick-up and provide everything needed to transport it as quickly as possible – even for short-term requests. Take a look at our overview of the procedure.
ASC Oncology was founded in 2019 by leading scientists in the fields of pathology, biology, biochemistry, biotechnology, and tumor biology. We are an interdisciplinary team of experts, who together with lawyers and business information specialists, are dedicated in our fight against cancer and to advance precision oncology.
ASC Oncology benefits from years of expertise in 3D cell culture and the latest findings in the field of tumor organoid research through close collaboration with its sister company CELLphenomics, which was founded in 2014. In addition, we are supported by a top-class advisory board consisting of physicians, scientists, and patient representatives.